Japan Blood Products Organization
Tokyo, Japan· Est.
A non-profit Japanese organization ensuring a stable, safe supply of blood-derived pharmaceutical products for hematology and rare disease treatments.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A non-profit Japanese organization ensuring a stable, safe supply of blood-derived pharmaceutical products for hematology and rare disease treatments.
HematologyRare DiseaseImmunology
Technology Platform
Large-scale plasma fractionation and pathogen inactivation technologies for the production of protein therapeutics derived from human blood.
Opportunities
Growth is driven by increasing clinical demand for plasma-derived therapies in an aging population and potential to expand product offerings through advanced fractionation techniques.
Risk Factors
Key risks include dependence on domestic plasma donation volumes, high fixed costs of manufacturing, and intense regulatory scrutiny over blood product safety.
Competitive Landscape
JB functions as a state-mandated domestic supplier, facing limited direct competition in Japan but competing indirectly with global plasma fractionators (e.g., Takeda, CSL Behring, Grifols) for technological benchmarks and international market share.